Longeveron explores options after trial fails
Longeveron is exploring strategic alternatives and cutting costs after its experimental stem cell therapy failed a mid-stage trial for an infant heart condition. The company will now shift its focus toward developing the treatment for aging-related frailty.
Xurve View
Insights:
Xurve View
Longeveron Inc. will explore strategic options after its experimental stem cell therapy failed a mid-stage trial, sending shares down 60% in after-hours trading on Wednesday evening. The setback halts development for a rare infant heart condition after the treatment missed its primary endpoint. United States regulators will meet with executives as the firm moves to cut costs and pivot toward aging-related frailty research.
